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Background: Hypertension related cardiovascular (CV) complications could be
amplified by the presence of metabolic co-morbidities. Azilsartan medoxomil (AZL-M)
is the eighth approved member of angiotensin II receptor blockers (ARBs), a drug class
of high priority in the management of hypertensive subjects with diabetes mellitus type II
(DMII).
Methods: Under this prism, we performed a systematic review of the literature for all
relevant articles in order to evaluate the efficacy, safety, and possible clinical role of AZL-M
in hypertensive diabetic patients.
Results: AZL-M was found to be more effective in terms of reducing indices of
blood pressure over alternative ARBs or angiotensin-converting enzyme (ACE) inhibitors
with minimal side effects. Preclinical studies have established pleiotropic effects for
AZL-M beyond its primary antihypertensive role through differential gene expression,
up-regulation of membrane receptors and favorable effect on selective intracellular
biochemical and pro-atherosclerotic pathways.
Conclusion: Indirect but accumulating evidence from recent literature supports the
efficacy and safety of AZL-M among diabetic patients. However, no clinical data exist to
date that evince a beneficial role of AZL-M in patients with metabolic disorders on top of
its antihypertensive effect. Further clinical studies are warranted to assess the pleiotropic
cardiometabolic benefits of AZL-M that are derived from preclinical research.
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INTRODUCTION
Hypertension bears an independent association with different indices of cardiovascular (CV)
disease, including stroke, myocardial infarction, heart failure, peripheral vascular atherosclerotic
disease and end-stage renal disease (Turnbull et al., 2005; Mancia et al., 2014). As clearly stated in
the latest European Society of Cardiology guidelines for the management of arterial hypertension,
the relationship between blood pressure (BP) and CV morbidity and mortality could be modified
by the concomitance of other CV risk factors (Thomas et al., 2001). In fact, metabolic risk factors
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are more common in hypertensive subjects. Along this line, the
prevalence of hypertension and diabetes mellitus are increasing
in parallel in industrialized and developing countries, commonly
coexist, and patients with both co-morbidities are particularly
vulnerable to CV disease and death (Hao et al., 2014). It is not
surprising that many patients suffer from CV events despite
adequate control of hypertension while on the other hand up to
75% of specific CV complications have been attributed to high BP
in diabetic patients (Chen et al., 2011). Under this prism,multiple
CV risk factor intervention is required to maximize target-organ
protection and should be strongly encouraged where possible
(Staessen et al., 2007).
Angiotensin II appears to exert a central role in both the
pathophysiology of essential hypertension and arteriosclerosis-
associated hypertension (Schmidt-Ott et al., 2000), and insulin
resistance (Olivares-Reyes et al., 2009). Therefore, an angiotensin
II receptor blocker (ARB) emerges as a reasonable therapeutic
strategy of high priority in the management of hypertensive
subjects with metabolic co-morbidities. While individual studies
reported controversial results regarding the effect of angiotensin-
converting enzyme (ACE) inhibitors/ARBs on CV risk in
hypertensive patients with type II diabetes mellitus (DMII), a
meta-analysis of randomized control studies concluded that this
class of drug is associated with significant reduction in CV events
and mortality (Hao et al., 2014). Until recently, there were seven
ARBs available in the market. Azilsartan medoxomil (AZL-M) is
the eighth approved ARB for the management of hypertension
(Angeli et al., 2013).
OBJECTIVE
Our objective was to evaluate the efficacy, safety, and possible
clinical role of AZL-M in hypertensive diabetic patients.
METHODS AND MATERIALS
A systematic review of the literature for all relevant articles was
performed until April 2016 using MEDLINE and COCHRANE
LIBRARY. The search strategy implemented the keywords
and MeSH terms: “azilsartan,” “azilsartan-medoxomil,” “TAK-
491,” “TAK-536,” “Edarbi,” AND “diabetes mellitus,” “type II,”
“glucose,” “insulin,” “resistance.” Articles were limited to those
published in the English language. Amanual search for references
from reports of clinical trials or review articles was performed
to identify additional relevant studies. Studies were deemed
eligible for inclusion when they evaluated in animals (both
in vitro and in vivo), and in human subjects the effect of AZL-
M. No further restrictions were imposed on the corresponding
recruited population of each study. An additional search
in Clinical—Trials.gov (http://www.clinicaltrials.gov) was also
conducted to identify recently completed or ongoing trials with
AZL-M.
Abbreviations: AZL-M, azilsartan medoximil; AII, angiotensin II; AT1,
angiotensin II receptor 1; IP1, inositol 1-phosphate; PPAR-γ, Peroxisome
proliferator-activated receptor gamma; eNOS, Endothelial Nitric Oxide System.
RESULTS
Pharmacology
AZL-M is the newest approved ARB for the management
of hypertension. It is a prodrug that is quickly hydrolyzed
to the active moiety azilsartan and reaches its peak plasma
concentration between 1.5 and 3 h following oral administration.
It is an ARBwith estimated bioavailability of 60% and elimination
half-life of 11 h. Metabolism of AZL-M occurs in the liver
via cytochrome P450 (CYP) 2C9 and to a lesser extent by
CYP2B6 and CYP2C8, resulting in the formation of inactive
metabolites. AZL-M is primarily excreted by the kidney, as
inactive metabolites, with a clearance of 2.3 mL/min (Angeli
et al., 2013). AZL-M is a potent and highly selective and
insurmountable AT1 receptor antagonist that binds tightly to and
dissociates slowly fromAT1 receptors compared with other ARBs
(Ojima et al., 2011). In particular, Ojima et al. using indirect
kinetic methods showed that AZL-M remained substantially
bound to the receptors after washout of the compound compared
with other ARBs, such as olmesartan, telmisartan, valsartan,
and irbesartan (Ojima et al., 2011) (Supplementary Table 1).
As a consequence, the inhibitory effect of AZL-M on AII
was reduced only by 25% 4 h after washout while inhibitory
effects of olmesartan, telmisartan, and valsartan were reduced
by 44, 70, and 99%, respectively (Supplementary Table 1).
In the same study, the inhibitory effects of AZL-M on IP1
accumulation and vasoconstriction induced by AII persisted even
after washout, whereas those of other ARBs, such as olmesartan
and valsartan were markedly attenuated (Supplementary Table
1). In regard to selectivity, AZL-M inhibited the vasoconstriction
induced by AII but not vasoconstriction induced by KCl,
norepinephrine, 5-hydroxytryptamine, or prostaglandin F2a
(Ojima et al., 2011). In addition, the authors reported that
AZL-M exhibited inverse agonism against AT1 receptors (Ojima
et al., 2011). The high-affinity and tight binding properties
of AZL-M are expected to induce potent and long-lasting
antihypertensive effects in preclinical and clinical settings while
inverse agonism may offer organ protective effects (Ojima
et al., 2011). Interestingly, in a small study of hemodialysis
patients with cross-over design, AZL-M exerted more prominent
suppression of sympathetic nervous system in comparison to
other ARBs that resulted in stronger anti-hypertensive effect
(Kusuyama et al., 2014). Sympatho-inhibition is a specific class
effect of ARBs (Nap et al., 2003), and can be quantified by
plasma noradrenaline levels—a sensitive index of the activity of
the sympathetic nervous system (Bakris et al., 2000). Thus, the
significant decrease in noradrenaline levels following substitution
of losartan, valsartan, telmisartan, or olmesartan with AZL-
M, suggests an amplified primary class effect for this member
of ARBs.
Preclinical Research and Metabolic Effects
of AZL-M
Although AZL-M has been approved for hypertension, it
remains to be determined whether this new drug can offer
clinical benefits beyond its hypertensive action (Kurtz and
Kajiya, 2012). In general, accumulating evidence suggests that
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ARBs could decelerate the progression of diabetic nephropathy,
independently of their BP lowering effect (Weber et al., 2014a;
Isaacs and Vincent, 2016). In addition, some ARBs may be more
effective than others in reducing proteinuria in patients with
diabetic nephropathy despite similar induced reductions in BP
(Kurtz and Kajiya, 2012). Most important, specific ARBs are
pleiotropic molecules with additional cellular actions beyond
the blockade of AT1 receptors that might confer favorable
cardiometabolic effects (Kurtz and Pravenec, 2008). According
to a relevant review study, ARBs typically have trivial impact
on basal glucose and insulin levels, particularly in lean animals,
but nonetheless often improve glucose and insulin sensitivity,
particularly in obese animals and/or models with type II
diabetes (Michel et al., 2016). In addition the authors mentioned
that AT1R blockade can improve diabetes-induced vascular
remodeling, probably independently of BP lowering (Michel
et al., 2016).
Several preclinical studies have shown beneficial effects
of AZL-M regarding pro-atherosclerotic pathways, insulin
sensitivity, and adipocyte differentiation (Iwai et al., 2007; Kajiya
et al., 2011; Kusumoto et al., 2011; Zhao et al., 2011; Lastra
et al., 2013; Tarikuz Zaman et al., 2013; Abdelsaid et al., 2014;
Matsumoto et al., 2014; Hye Khan et al., 2014a,b; Liu et al.,
2016). In specific, Kajiya et al. investigated pleiotropic features
of AZL-M in cell-based assay systems independently of its effects
on blood pressure and showed that AZL-M, but not valsartan,
blocked AII-induced activation of mitogen-activated protein
kinases (MAPK) in vascular smooth muscle cells (VSMCs)
after delayed washout of the drug (Kajiya et al., 2011). This
phenomenon is consistent with the intrinsic high-affinity and
tight binding properties of AZL-M (Ojima et al., 2011). However,
in the same study AZL-M exerted anti-proliferative effects in
vascular cells in the absence of AII, that could be explained by its
inverse agonist properties, but also in cells lacking AT1 receptors,
suggesting involvement of mechanisms beyond AT1 receptor
blockade. Moreover, according to the authors AZL-M impelled
a favorable differentiation of adipocytes and exerted stimulatory
effects on the expression of genes for PPARa, PPARd, leptin,
adipsin, and adiponectin in comparison to a less pronounced
effect of valsartan (Kajiya et al., 2011).
On the other hand, animal studies converge that AZL-M is
efficient in reducing insulin resistance. Zhao et al. reported that
AZL-M improves insulin sensitivity in obese spontaneously
hypertensive Koletsky rats and this effect may involve
regulation of 11β-HSD1 activity (Zhao et al., 2011). In type
II diabetic KK-Ay mice, AZL-M was superior to candesartan in
improving glucose intolerance, insulin sensitivity, and inducing
beneficial adipocyte differentiation (Iwai et al., 2007). Authors
suggested that AZL-M exhibited these effects by reducing TNF-a
production and increasing of the expression of PPARγ, C/EBP,
and aP2 more effectively than candesartan (Iwai et al., 2007).
Toward this direction, an additional study reported that AZL-M
improved the in vitro insulin effect on glucose transport in
red soleus muscle and on the intracellular signaling cascade in
the red gastrocnemius muscle in AII-induced insulin-resistant
rats (Lastra et al., 2013). The favorable actions of AZL-M in
this animal model might be associated with insulin signaling
regulation and specifically enhanced AMPKα expression and
suppressed p70 S6K1 activation (Lastra et al., 2013).
Recently, AZL-M reduced diabetic kidney damage in Zucker
diabetic fatty rats and this effect was accompanied by improved
glycemic status, improved vascular homeostasis, reduced BP, and
reduced oxidative stress and inflammation (Hye Khan et al.,
2014a). In animal models of hypertension and DMwith evidence
of nephropathy, AZL-M induced superior antihypertensive,
insulin-sensitizing and anti-proteinuric effects as compared to
olmesartan medoxomil (Kusumoto et al., 2011). Results from
another animal study suggest that azilsartan restores endothelial
function more effectively than does candesartan cilexetil, by
normalizing eNOS function and by reducing inflammation and
oxidative stress in diabetic mice (Matsumoto et al., 2014).
According to the authors, higher affinity for and slower
dissociation from AT1 receptors may underlie AZL-M efficacy
in diabetic vascular dysfunction (Matsumoto et al., 2014).
Despite consistent favorable effects of AZL-M in nonclinical
studies, the metabolic pathways activated by AZL-M in terms
of improved insulin sensitivity are not fully elucidated. For
example, PPAR-γ is an intracellular receptor involved in the
regulation of glucose and lipid metabolism and has gained
increasing attention as a novel therapeutic target (Kurtz and
Pravenec, 2008). Iwai et al. reported an upregulated expression
of PPARγ in adipose tissue (Iwai et al., 2007), but Zhao et al.
failed to reproduce this effect (Zhao et al., 2011). In support of
the results from Iwai et al., additional data have linked AZL-M
with protection of brain endothelial cells from oxidative stress,
through preserved mitochondrial function, eNOS mediated anti-
inflammatory activity and activation of the PPAR-γ pathway (Liu
et al., 2016). Finally, cumulative evidence from other animal
studies further strengthens the beneficial cardiovascular effects
of AZL-M under settings of unfavorable metabolic profile (i.e.,
DM or increased insulin resistance, Tarikuz Zaman et al., 2013;
Abdelsaid et al., 2014; Hye Khan et al., 2014b). Of note, an
observation of clinical significance is that AZL-M in doses similar
to those used in humans can improve insulin sensitivity much
more than larger doses of other ARBs, such as olmesartan
medoxomil or candesartan cilexetil (Iwai et al., 2007; Kusumoto
et al., 2011).
Evidence from Clinical Trials
Anti-Hypertensive Effects of AZL-M in Comparison to
Other ARBs
A number of double-blind randomized clinical trials have
investigated the antihypertensive efficacy and safety of AZL-M
compared to other ARBs (Bakris et al., 2011; Sica et al., 2011;
White et al., 2011; Rakugi et al., 2012; Table 1). AZL-M was
compared with olmesartan in two trials (Bakris et al., 2011;
White et al., 2011), with valsartan in two trials (Sica et al.,
2011; White et al., 2011), and with candesartan in one trial
(Rakugi et al., 2012). The trials ranged in duration from 6 to
24 weeks while the recruited population ranged from 622 to
1291 participants. AZL-M was found to be more effective toward
the primary end point of reduction in office or ambulatory
systolic BP over each of its comparators. Adverse events were
reported similarly in all treatment groups and were mostly mild
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TABLE 1 | Clinical trials comparing azilsartan medoxomil as a monotherapy or in specific drug combinations to established antihypertensive medication.
Study (year) Type of study Patients Duration Treatment Primary end-point Result
AZILSARTAN MEDOXOMIL(AZL-M) AS MONOTHERAPY
Bakris et al., 2011 Double–blind RCT 1275 6 weeks AZL-M $20,40,80mg or OLM
40mg or placebo
Change from baseline in
24-h mean SBP
AZL-M 80mg (−14.6 mmHg) vs.
OLM (−12.6 mmHg) (p = 0.038)
AZL-M 40mg (−13.4 mmHg) was
non-inferior to OLM 40 mg
White et al., 2011 Double–blind RCT 1291 6 weeks AZL-M 40,80mg or VAL
320mg or OLM 40mg or
placebo
Change from baseline in
24-h mean SBP
AZL-M 80mg (−14.5 mmHg) vs.
OLM (–12.0 mmHg) (p = 0.009) and
VAL (−10.2 mmHg) (p < 0.001)
AZL-M 40mg (−13.4 mmHg) was
non-inferior to OLM 40 mg
Sica et al., 2011 Double–blind RCT 984 24 weeks AZL-M 40,80mg or VAL
320 mg
Change from baseline in
24-h mean SBP
AZL-M 40mg (−14.9 mmHg) and
80mg (−15.3 mmHg) vs. VAL
(−11.3 mmHg) (p < 0.001 for both)
Rakugi et al., 2012 Double–blind RCT 622 16 weeks AZL-M 20–40mg or CAND
8–12 mg
Change from baseline in
the sitting trough DBP
AZL-M (−12.4 mmHg) vs. CAND
(−9.8 mmHg) (p = 0.0003)
Bönner et al.,
2013
Double–blind RCT 884 24 weeks AZL-M 20–80mg or RAM
2.5–10 mg
Change from baseline in
the sitting trough SBP
AZL-M 40mg (−20.6 mmHg) and
AZL-M 80mg (−21.2 mmHg) vs.
RAM (–12.2 mmHg) (p < 0.001)
Kario and
Hoshide, 2015
Open-label RCT* 718 8 weeks AZL-M 20mg or AML 5 mg Differences between
sleep SBP
AZL-M 20mg (−12.6 mmHg) vs.
AML 5mg (−17.5 mmHg) (p <
0.001)
EARLY Gitt et al.,
2016
Observational,
prospective**
3849 12 months AZL-M or any ACE-i Documentation of the
achievement of target BP
values set according to
recent guidelines
Description of the safety
profile of AZL-M
Target BP level achieved in AZL-M
group (61.1% of patients) vs. ACE-I
group (56.4% of patients) (p < 0.05)
Equivalent safety profile (p = 0.73)
AZILSARTAN MEDOXOMIL AS COMBINATION
Bakris et al., 2012 Double–blind RCT 609 10 weeks AZL-M/CLD
40/12.5–40/25mg or
AZL-M/HCTZ 40/12.5–40/25
mg
Change from baseline in
clinic SBP
AZL-M/CLD 40/12.5mg (−35.1
mmHg) vs. AZL-M/HCTZ 40/12.5
(−29.5 mmHg) (p < 0.001)
Sica et al., 2012 Double–blind RCT 1714 8 weeks AZL-M 0,20,40,80mg and/or
CLD 0, 12.5, 25 mg
Change from baseline in
trough SBP by ABPM
AZL-M/CLD 40/25 and 80/25mg
(−28.9 mmHg) vs. AZL-M 80mg
(−15.1 mmHg) and CLD 25mg
(−15.9 mmHg) (p < 0.001 for both)
Cushman et al.,
2012
Double–blind RCT 1071 12 weeks AZL-M/CLD 40/25mg or
AZL-M/CLD 80/25mg or
OLM/HTCZ 40/25 mg
Changes from baseline in
trough, seated, clinic
SBP
AZL-M/CLD 40/25mg (−42.5
mmHg) and AZL-M/CLD 80/25mg
(−44.0 mmHg) vs. OLM/HTCZ
40/25mg (−37.1 mmHg) (p < 0.001)
Weber et al.,
2014b
Double–blind RCT 566 6 weeks AZL-M/AML 40/5,80/5mg or
AML 5mg + placebo
Change from baseline in
24-h SBP
AZL-M/AML 40/5mg (−24.8 mmHg)
and AZL-M/AML 80/5mg (−24.5
mmHg) vs. AML 5mg + placebo
(13.6 mmHg) (p < 0.001)
Rakugi et al., 2014 Double–blind RCT 603 8 weeks AZL-M/AML 20/5mg or
AZL-M/AML 20/2.5mg or
AZL 20mg or AML 5mg or
AML 2.5 mg
Change from baseline in
the seated trough DBP
AZL-M/AML 20/5mg (−35.3 mmHg)
and AZL-M/AML 20/2.5mg (−31.4
mmHg) vs. AZL-M 20mg (−21.5
mmHg), AML 5mg (−26.4 mmHg),
AML 2.5mg (−19.3 mmHg) (p <
0.001)
Kipnes et al., 2015 Double-
blindRCT***
299 6 weeks AZL-M ± CLD ± other
antihypertensive or
Placebo±CLD ± other
antihypertensive (depending
on the open-label phase)
Change in trough clinic
sitting DBP
Mean difference between AZL-M and
placebo (−7.8 mmHg) (p < 0.001)
*Multicenter, randomized, open-label, 2-parallel-group study.
**Prospective, observational, national, multicenter registry.
***26-week, open-label, titrate-to-target study, followed by a 6-week, double-blind, placebo-controlled reversal phase. Only double-blind reversal phase is reported.
RCT, randomized controlled trial; AZL-M, Azilsartan Medoxomil; OLM. olmesartan; RAM, ramipril; VAL, valsartan; CAND, candesartan; ACEi, angiotensin converting enzyme inhibitor;
HCTZ, hydroclorothiazide; CLD, clorthalidone; AML, amlodipine; SBP, systolic blood pressure; DBP, diastolic blood pressure; BP, blood pressure; ABPM, ambulatory blood pressure
monitoring.
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to moderate in severity, including mainly dizziness, headache,
urinary infection, and upper-respiratory tract inflammation.
The incidence of treatment-associated adverse events ranged
from 35.9 to 65.4% for AZL-M and from 37.9 to 59.2% for
alternative ARBs and no significant differences were established
for all pairwise comparisons in individual studies (p > 0.05
for all; Bakris et al., 2011; Sica et al., 2011; White et al., 2011;
Rakugi et al., 2012). Discontinuations due to adverse events
were infrequent in all groups. In detail, discontinuation rates
for AZL-M ranged from 1.1 to 8.2% as compared with 1.3 to
6.1% for other ARBs (p > 0.05 for individual comparisons;
Bakris et al., 2011; Sica et al., 2011; White et al., 2011;
Rakugi et al., 2012). It should be emphasized that the clinical
trials that established the efficacy of AZL-M, analyzed data
from 24-h ambulatory blood pressure monitoring (ABPM) for
comparisons with alternative antihypertensive agents, in addition
to other hemodynamic indices. ABPM provides more reliable
predictive data on cardiovascular outcomes than conventional
office readings (Fagard et al., 2008). Superiority of AZL-M in
lowering BP during a 24 h period could be partially explained by
its selective binding and tighter binding properties (Ojima et al.,
2011).
Metabolic Effects of AZL-M in Comparison to Other
ARBs
Notable exclusion criteria for most clinical trials assessing
AZL-M were previous history of major cardiovascular events
or significant cardiac conduction abnormalities, severe renal
impairment as well as type I or poorly controlled type II diabetes.
As a result, there is limited evidence regarding treatment with
AZL-M in diabetic patients. However, three out of the four
clinical trials reported the recruitment of patients with well
controlled DMII (HbAc1 <8 mg/dl; Bakris et al., 2011; Sica
et al., 2011; White et al., 2011). Although no pre-specified
subgroup analysis for the presence of DMII was provided in
these studies, we can assume that AZL-M may be effective and
well-tolerated in the subgroup of diabetic patients as part of the
total population. This assumption is reinforced by the results
of the fourth trial by Rakugi et al. (2012). Diabetic patients
were included without any limitations and the subgroup analysis
based on the presence of DM showed similar effectiveness
of AZL-M in the diabetic subgroup compared to the non-
diabetic and superiority over candesartan in diabetic subgroup
(Rakugi et al., 2012). For all randomized studies of AZL-M vs.
alternative ARBs authors did not establish changes in metabolic
parameters that could indicate a beneficial metabolic profile of
AZL-M in diabetic patients. In a recent meta-analysis of three
of the four randomized controlled clinical trials mentioned, the
efficacy, safety and metabolic effects of AZL-M were compared
to alternative ARBs (valsartan and olmesartan), separately in
patients with impaired fasting glucose (prediabetes mellitus) and
DM (White et al., 2016). A total of 3821 patients were randomized
to either AZL-M, olmesartan, valsartan, or placebo and further
stratified by subgroups of normoglycemic, prediabetic, and DM
status. AZL-M exhibited more potent antihypertensive efficacy
than olmesartan or valsartan in patients with prediabetes mellitus
and DM based on both office and ambulatory BP results. As far as
metabolic parameters were concerned (including among others
blood glucose, insulin levels, and biomarkers, such as adiponectin
and lipoproteins), no significant differences were established
among treatment subgroups. The authors commented that the
short-term nature of the trials incorporated in their pooled
analysis may have masked potential beneficial effects of AZL-M
on certain metabolic parameters (White et al., 2016).
AZL-M as a Combination with Chlorthalidone
AZL-M was also evaluated for its antihypertensive effect when
administered in combination with chlorthalidone (CLD) (Bakris
et al., 2012; Cushman et al., 2012; Sica et al., 2012; Table 1).
Fixed-dose combinations of AZL/CLD were compared to their
individual monotherapies (Sica et al., 2012), to the combination
of AZL/hydrochlorothiazide (HCTZ) (Bakris et al., 2012) and
with fixed-dose combinations of olmesartan/HCTZ (Cushman
et al., 2012). Regarding the primary outcome of reduction from
baseline in office systolic BP or 24-h BP, the combination of
AZL/CLD was consistently more efficient than its comparators
(Bakris et al., 2012; Cushman et al., 2012; Sica et al., 2012).
In addition, another study evaluated the efficacy and safety
of AZL-M alone and with CLD (Kipnes et al., 2015). Both
treatment strategies met the primary endpoint of significant
reduction in office change diastolic BP with concomitant long-
term stable improvements in BP. The therapeutic effect of
AZL/CLD observed in mentioned trials was accompanied by
good safety and tolerability (Bakris et al., 2012; Cushman et al.,
2012; Sica et al., 2012; Kipnes et al., 2015; Table 1).
Anti-Hypertensive Effects of AZL-M in Comparison to
Other Drug Classes
For comparisons with different classes of antihypertensive drugs,
data on the efficacy, and safety of AZL-M are limited (Bönner
et al., 2013; Rakugi et al., 2014; Weber et al., 2014b; Kario and
Hoshide, 2015; Gitt et al., 2016; Table 1). As far as comparisons
with ACE inhibitors are concerned, a trial evaluated the efficacy
and safety of AZL-M vs. ramipril after 24 weeks of treatment.
AZL-Mwas superior to ramipril in reducing all measured indices
of BP (trough, clinic, and ambulatory). The safety profile was
similar to that of ramipril, with fewer discontinuations due
to adverse events (Bönner et al., 2013; Table 1). Albeit not
randomized, the one-year outcomes of the EARLY registry, a
prospective observational study that was designed to compare
AZL-M with ACE-inhibitors under real life settings, further
reinforce the results of the aforementioned clinical trials and
confirm the greater BP-lowering effect of AZL-M (Gitt et al.,
2016; Table 1).
Two randomized trials compared AZL-M in combination
with amlodipine with their individual monotherapies (Rakugi
et al., 2014), and with amlodipine plus placebo (Weber et al.,
2014b), respectively. Changes from baseline in the sitting, trough,
diastolic BP and 24 h systolic BP were considered the primary
end point and combination of the two drugs was found to
be a more efficient regimen than individual monotherapy and
placebo along with a similar safety profile (Rakugi et al., 2014;
Weber et al., 2014b). In contrast, when AZL-M was compared
with amlodipine in a randomized, open-label study (N = 718),
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AZL-M failed to induce a greater reduction in night systolic BP
than amlodipine after 8-weeks of treatment (Kario and Hoshide,
2015).
DISCUSSION
Based on the preclinical studies (Iwai et al., 2007; Kajiya et al.,
2011; Kusumoto et al., 2011; Zhao et al., 2011; Lastra et al., 2013;
Tarikuz Zaman et al., 2013; Abdelsaid et al., 2014; Hye Khan et al.,
2014a,b; Matsumoto et al., 2014; Liu et al., 2016), AZL-M emerges
as a pleiotropic drug that may exert beneficial cardiometabolic
effects beyond its antihypertensive properties (Figure 1). These
favorable effects are more profound in comparison to other
ARBs, probably due to higher affinity, tighter binding, and slower
dissociation from AT1 receptors. This superiority was observed
even when AZL-M was used in therapeutic doses in comparison
to other ARBs that were administered above recommended
clinical doses (Iwai et al., 2007; Kusumoto et al., 2011). According
to the investigators, the proposed mechanisms of pleiotropic
effects are mostly related to AT1 receptor. However, in cellular
level there is evidence of actions beyond AT1 receptor (Kajiya
et al., 2011). Experimental studies mentioned before converge
in the activation of PPARγ pathway from AZL-M as a possible
favorable pathophysiological mechanism on top of the AT1
receptor blockage but data is controversial or at least limited
in clinical level (Kurtz and Klein, 2009). In general, preclinical
trials support AZL-M as a possible beneficial treatment strategy
for diabetic patients, beyond its antihypertensive effect. However,
no such evidence can be supported from clinical data. Based
on the results of up-to date clinical trials (Bakris et al., 2011,
2012; Sica et al., 2011, 2012; White et al., 2011; Cushman et al.,
2012; Rakugi et al., 2012, 2014; Bönner et al., 2013; Weber et al.,
2014b; Kario and Hoshide, 2015; Kipnes et al., 2015; Gitt et al.,
2016), AZL-M is a potent and well-tolerated antihypertensive
drug and, furthermore, there is indirect evidence of its efficacy
and safety among diabetic patients. In comparison to other
ARBs, the superior antihypertensive effect of AZL-M could
be attributed to its unique binding properties and, according
to a small study (Kusuyama et al., 2014) to the greater
suppression of sympathetic nervous system. Moreover, it is
efficient when combined with other antihypertensive drugs.
At present, there are no large clinical trials assessing the
effect of AZL-M on metabolic profile and on cardiovascular
morbidity and mortality. Supplementary Table 2 provides a
FIGURE 1 | Possible pleiotropic effects and proposed mechanisms in subjects with unfavorable metabolic profile combined with antihypertensive
properties of azilsartan medoximil.
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quick reference on the role of AZL-M in the cardiovascular
system as assessed by up to date preclinical research and clinical
trials.
CONCLUSION
In conclusion, AZL-M is an effective and safe BP lowering
drug for patients with hypertension and metabolic co-
morbidities, including DM or prediabetes mellitus. Pleiotropic
cardiometabolic benefits of AZL-M have emerged and
validated in preclinical research but should be confirmed
and further evaluated in large scale clinical trials. It is now
reported on ClinicalTrials.gov that relevant trials have been
designed and have proceeded to the recruitment phase.
We anticipate primary results from these trials to fully
adjudicate AZL-M as the most promising member of the
ARB class toward primary and secondary cardiometabolic
prevention.
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